Dietary and pharmacological management of severe catabolic conditions

American Journal of the Medical Sciences

Volumn 342, Issue 6, 2011, Pages 513-518

  Elamin, E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anorexia; Cachexia; Chronic illness; Malnutrition; Pharmacological therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIULCER AGENT; APPETITE STIMULANT; C REACTIVE PROTEIN; CYPROHEPTADINE; CYTOKINE; CYTOKINE ANTIBODY; DEXAMETHASONE; DRONABINOL; GHRELIN; GLUCOCORTICOID; GROWTH HORMONE; HORMONE RECEPTOR BLOCKING AGENT; LEPTIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MELANOCORTIN 4 RECEPTOR ANTAGONIST; MYOSTATIN ANTIBODY; NABILONE; NANDROLONE DECANOATE; NEUROPEPTIDE Y; PREDNISOLONE; PROBIOTIC AGENT; PROTEASOME; THALIDOMIDE; UBIQUITIN; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ANOREXIA; ANTIBIOTIC THERAPY; ARCUATE NUCLEUS; ARTICLE; BREAKTHROUGH BLEEDING; CACHEXIA; CANCER CHEMOTHERAPY; CONFUSION; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIARRHEA; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTERIC FEEDING; EUPHORIA; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INCREASED APPETITE; METABOLIC DISORDER; MUSCLE ATROPHY; NONHUMAN; NUTRITIONAL STATUS; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PEPTIC ULCER; PERIPHERAL EDEMA; PROTEIN BLOOD LEVEL; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THROMBOEMBOLISM; UTERUS BLEEDING; VOMITING; WEIGHT REDUCTION;

EID: 82355185966     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31821cc47f     Document Type: Review

References (44)

1. Lundholm K, Daneryd P, Bosaeus I, et al. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function. Cancer 2004;100:1967-77. (Pubitemid 38529575)
2. Sullivan DH, Bopp MM, Roberson PK. Protein-energy undernutrition and life-threatening complications among the hospitalized elderly. J Gen Intern Med 2002;17:923-32. (Pubitemid 35471990)
3. Thomas DR, Zdrowski CD, Wilson MM, et al. Malnutrition in subacute care, Am J Clin Nutr 2002;75:308-13. (Pubitemid 34101217)
4. Mustafa I, Leverve X. Metabolic and nutritional disorders in cardiac cachexia. Nutrition 2001;17:756-60. (Pubitemid 32816331)
5. Koehler F, Doehner W, Anker SD, et al. Anorexia in chronic obstructive pulmonary disease-association to cachexia and hormonal derangement. Int J Cardiol 2007;119:83-9. (Pubitemid 46818476)
6. Laviano A, De Luca S, Meguid MM, et al. Cancer anorexia: a neglected issue in the optimal management of cancer patients. J Cancer Pain Sympt Pall 2005;1:15-24. (Pubitemid 44195489)
7. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404:661-71. (Pubitemid 30205071)
8. Finck BN, Johnson RW. Tumor necrosis factor-a regulates secretion of the adipocyte-derived cytokine, leptin. Microsc Res Tech 2000;3: 209-15. (Pubitemid 30610097)
9. Pines J, Lindon C. Proteolysis: anytime, anyplace, anywhere? Nat Cell Biol 2005;7:731-5.
10. Abbatecola AM, Ferrucci L, Grella R, et al. Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc 2004;52:399-404. (Pubitemid 38339521)
11. Morley JE. Weight loss in older persons: new therapeutic approaches. Curr Pharm Des 2007;13:3637-47. (Pubitemid 350238934)
12. Elamin EM, Camporesi E. Evidence-based nutritional support in the intensive care unit. Int Anesthesiol Clin 2009;47:121-38.
13. Fearon KC, Voss AC, Hustead DS; Cancer Cachexia Study Group. Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006;83:1345-50. (Pubitemid 44713065)
14. August DA, Huhmann MB. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009;33:472-500.
15. Reynolds JV, Kanwar S, Welsh FK, et al. 1997 Harry M. Vars Research Award: does the route of feeding modify gut barrier function and clinical outcome in patients after major upper gastrointestinal surgery? JPEN J Parenter Enteral Nutr 1997;21:196-201. (Pubitemid 27318389)
16. Bozzetti F, Arends J, Lundholm K, et al. ESPEN guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr 2009;28:445-54.
17. Arends J, Bodoky G, Bozzetti F, et al. ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006;25:245-59. (Pubitemid 43811685)
18. Whitehouse AS, Smith HJ, Drake JL. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapenta-enoic acid. Cancer Res 2001;61:3604-9. (Pubitemid 32694970)
19. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12:27-30.
20. Miller AC, Elamin EM. Efficacy of enteral nutrition with eicosapen-taenoic acid and gamma-linolenic acid in patients with ARDS and MODS: a prospective multi-center randomized controlled trial. Am J Respir Crit Care Med 2009;179:A4625.
21. Miller AC, Elamin EM. Probiotics for treatment of chemotherapy-induced diarrhea: Is it a myth? JPEN 2009;33:573-4.
22. Elamin EM, Glass M, Camporesi E. Pharmacological approaches to ameliorating catabolic conditions. Curr Opin Clin Nutr Metab Care 2006;9:449-54. (Pubitemid 44097816)
23. Mitchelson F. Pharmacological agents affecting emesis: a review. Drugs 1992;43:295-15.
24. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endo-cannabinoids are involved in maintaining food intake. Nature 2001;410: 822-5. (Pubitemid 32303781)
25. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multi-center, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24:3394-400. (Pubitemid 46638895)
26. Yeh S, Wu SY, Levine DM, et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging 2000;4:246-51. (Pubitemid 32045673)
27. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005: CD004310.
28. Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systemic review of randomized clinical trials. Ann Oncol 2001;12:289-300. (Pubitemid 32288683)
29. Thomas DR. Incidence of venous thromboembolism in megestrol acetate users. J Am Med Dir Assoc 2004;5:65-6.
30. Nagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary associated ca-chexia. Intern Med 2006;45:127-34. (Pubitemid 43349437)
31. Kamiji MM, Inui A. The role of ghrelin and ghrelin analogues in wasting disease. Curr Opin Clin Nutr Metab Care 2008;11:443-51.
32. Stanley BG, Kyrkouli SE, Lampert S, et al. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical in-ducer of hyperphagia and obesity. Peptides 1986;7:1189-92. (Pubitemid 17226746)
33. De Boer MD, Marks DL. Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab 2006;2:459-66. (Pubitemid 44214068)
34. Cuerda C, Zugasti A, Breton I, et al. Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men. Nutr Clin Pract 2005;20:93-7. (Pubitemid 40261944)
35. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discover Today 2007;12:241-8.
36. Evans WJ, Smith M, Morley JE, et al. Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: implications for cancer cachexia patients, 2007 Annual Meeting Proceedings Part I. J Clin Oncol 2007;25:9119.
37. Meguid MM, Fetissov SO, Varma M, et al. Hypothalamic dopa-mine and serotonin in the regulation of food intake. Nutrition 2000;16:843-57.
38. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991;67:33-6.
39. Edelman MJ, Gandara DR, Meyers FJ, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 1999;86:684-8. (Pubitemid 29379415)
40. Joulia-Ekaza D, Cabello G. The myostatin gene: physiology and pharmacological relevance, Curr Opin Pharmacol 2007;7:310-5. (Pubitemid 46738500)
41. Costelli P, Muscaritoli M, Bonetto A, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008;38:531-8. (Pubitemid 351832040)
42. Eleutherakis-Papaiakovou V, Bamias A, et al. Thalidomide in cancer medicine. Ann Oncol 2004;15:1151-60. (Pubitemid 39199301)
43. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. GUT 2005;54:540-5. (Pubitemid 40403032)
44. Tassinari D, Santelmo C, Tombesi P, et al. Thalidomide in the treatment of cancer cachexia. J Palliat Care 2008;24:187-9.